Pharmaceutical Market: India A Comprehensive Industry Analysis Q3 2013

  • November 2013
  • -
  • Kelly Scientific Publications
  • -
  • 161 pages

“Pharmaceutical Market: India, A Competitive Industry Analysis Q3 2013” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. This report describes the current therapeutics that are propelling the biopharmaceutical market in India and the main players in the industry. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets and is supported by over 330 exhibits. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

The main objectives of this report are:

• To comprehensively summarize current developments in the Indian biopharmaceutical industry.
• To identify emerging trends in key markets and sub-markets such as biogenerics, cardiology, oncology therapeutics, diabetic care, vaccines and anti-infective agents.
• To comprehensive review and analyse financial and product details of key players in the industry
• To present market figures of the current Indian biopharmaceutical market value and give forecast projections and growth rates
• To identify key drivers and restraints of the Indian biopharmaceutical market
• To report and analyse market opportunities and challenges
• To identify funding and government sponsorship issues

The reader of this report will gain:

• An in-depth understanding of the Indian biopharmaceutical market and it’s environment
• Current market facts, figures and product lines of key players in the industry
• An insight into how generic therapeutics will propagate the Indian biopharmaceutical market
• Knowledge of how the Indian biopharma market will integrate into the global healthcare market
• Information on key government policies
• Data on levels of private and publically funded biopharma studies in India
• Strategies on how to adapt and restructure current business models to this industry

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. The following companies were chosen for analysis as they have specific advantages that we believe will drive the pharmaceutical industry in India.

• Aurobindo Pharma
• Bharat Serums and Vaccines Ltd
• Biocon Biopharmaceuticals
• Cipla
• Divis Laboratories
• Dr Reddy’s Laboratories
• Lupin
• Mankind Pharma
• Panacea Biotech
• Piramal Group
• Ranbaxy Laboratories
• Reliance Life Sciences
• Serum Institute of India
• Sun Pharmaceuticals
• Zydus Cadila

Table Of Contents

Table of Contents

1.0 Summary 9
1.1 Objectives of Report 9
1.2 Scope of Study 10
1.3 Data Sources and Methodology 10
1.4 Key Findings and Observations 10
1.5 Executive Summary 11
2.0 Epidemiology and Disease Overview 15
2.1 Cardiovascular Disease 19
2.2 Infectious Disease 21
2.3 Respiratory Infections 21
2.4 Tuberculosis 23
2.5 HIV 28
2.6 Hepatitis 29
2.7 Typhoid Fever 30
2.8 Dengue Fever 30
2.9 Diabetes 30
2.10 Cancer 32
2.11 Chronic Respiratory Disease- Asthma and COPD 36
3.0 Twelfth Five Year Plan - A Boost for Scientific Research and Development 38
4.0 Economic and Business Environment 40
4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 40
4.2 Gross Domestic Product of India, Historic and Projection Analysis 42
4.3 Global and India Economic Outlook 2010-2013 43
4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe) 45
5.0 Indian Pharmaceutical Industry 48
5.1 Overview 48
5.2 Formulations Market 49
5.3 Active Pharmaceutical Ingredient Market 50
5.4 Biosimilar Market 51
5.5 Contract Research and Manufacturing Service (CRAMS) 52
5.6 Indian Pharmaceutical Industry Market 53
5.7 Evaluation of Market Share by Therapeutic Area 56
5.8 Key Players 57
6.0 Indian Pharmaceutical Company Profiles and Financial Data 59
6.1 Aurobindo Pharma 59
6.2 Bharat Serums and Vaccines Ltd 66
6.3 Biocon Biopharmaceuticals 68
6.4 Cipla 77
6.5 Divis Laboratories 82
6.6 Dr Reddy’s Laboratories 84
6.7 Lupin 89
6.8 Mankind Pharma 101
6.9 Panacea Biotech 106
6.10 Piramal Group 114
6.11 Ranbaxy Laboratories 119
6.12 Reliance Life Sciences 127
6.13 Serum Institute of India 130
6.14 Sun Pharmaceuticals 133
6.15 Zydus Cadila 137
7.0 SWOT Analysis of Indian Pharmaceutical Market 144
7.1 Growth Factors 144
7.2 Strengths of Indian Pharmaceutical Industry 145
7.3 Main Weaknesses 145
7.4 Significant Opportunities within the Indian Pharmaceutical Industry 146
7.5 Threats and Considerations 147
8.0 Company Directory and Key People 149
8.1 Aurobindo Pharma 149
8.2 Bharat Serums and Vaccines Ltd 150
8.3 Biocon Biopharmaceuticals 151
8.4 Cipla 153
8.5 Divis laboratories 153
8.6 Dr Reddy’s Laboratories 155
8.7 Lupin 157
8.8 Panacea Biotech 158
8.9 Reliance Life Sciences 160
9.0 Appendix 161
9.1 Comprehensive List of Pharmaceutical Company’s in India 161

Exhibit List

Exhibit 2.1: Key Statistics: India 15
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 - 2011 15
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030 17
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India 17
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030 18
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030 18
Exhibit 2.7: Cardiovascular Mortality by Indian State 19
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India 20
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India 21
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia 22
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children 22
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present 23
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011 24
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse
and HIV Co-infection 24
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011 25
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011 26
Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011 26
Exhibit 2.18: TB Vaccine Development Pipeline 2012 27
Exhibit 2.19: HIV Prevalence in India 2004-2009 28
Exhibit 2.20: Routes of HIV Transmission in India 2011 28
Exhibit 2.21: Global Hepatitis E Virus Endemicity 29
Exhibit 2.22: Prevalence of Diabetes by Indian Region 31
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011 31
Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India - Both Sexes 32
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female 33
Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men 33
Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India - Women 34
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes 34
Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes 35
Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer’s in India 35
Exhibit 2.30: Mortality Rate Attributable to Chronic Obstructive Pulmonary Disease Globally 36
Exhibit 3.1: India’s Twelve Year Plan - Key Points in Relation to Science Research and Development 39
Exhibit 3.2: Budget for Specific Scientific Departments under India’s Twelfth Five Year Plan 39
Exhibit 4.1: World Trade Organisation Basic Indicators on India 40
Exhibit 4.2: World Trade Organisation Trade Policy of India 40
Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India 41
Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India 41
Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India 41
Exhibit 4.6: India GDP Figures 2011-2018 42
Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010 42
Exhibit 4.8: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 43
Exhibit 4.9: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010- 2013 43
Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013 44
Exhibit 4.11: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013 44
Exhibit 4.12: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 44
Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013 45
Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017 45
Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013 46
Exhibit 4.16: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 46
Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013 47
Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013 47
Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017 47
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry 48
Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015 49
Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015 49
Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015 50
Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015 50
Exhibit 5.6: Geographic Distribution of India’s Active Pharmaceutical Ingredient Exports, 2012 51
Exhibit 5.7: Current Trends of the Global Biosimilar Market 51
Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market 52
Exhibit 5.9: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry 52
Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry 52
Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015 53
Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market 54
Exhibit 5.13: India - Significant Economic Indicators 54
Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market 55
Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012 55
Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011 56
Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market 56
Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area 56
Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012 57
Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market 57
Exhibit 5.21:Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue 57
Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market 58
Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012 58
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest 59
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation 59
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations 59
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest 60
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio 60
Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio 60
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio 61
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio 61
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio 61
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio 61
Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio 61
Exhibit 6.12: Aurobindo Pharma Alzheimer’s Product Portfolio 61
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio 61
Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio 62
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio 62
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio 62
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio 62
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio 63
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio 63
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio 63
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012 65
Exhibit 6.22: Aurobindo Pharma Subsidiary Companies 65
Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies 66
Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones 67
Exhibit 6.25: Bharat Serums and Vaccines Range of Products 67
Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio 67
Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio 68
Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio 68
Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio 68
Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio 68
Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio 68
Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio 68
Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio 68
Exhibit 6.34: Biocon Biopharmaceuticals Business Outline 69
Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas 69
Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies 70
Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones 70
Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas 72
Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas 72
Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations 72
Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics 72
Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics 73
Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics 73
Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics 73
Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics 74
Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics 74
Exhibit 6.47: Biocon Biopharmaceuticals - Syngene Service Platform 75
Exhibit 6.48: Biocon Biopharmaceuticals - Clinigene Service Platform 75
Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012 76
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012 76
Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012 77
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012 77
Exhibit 6.53: Cipla Important Milestones 78
Exhibit 6.54: Cipla Main Therapeutics Areas of Interest 78
Exhibit 6.55: Cipla Export Market Share FY2011-2012 79
Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012 80
Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012 80
Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012 81
Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012 81
Exhibit 6.60: Divis Laboratories Important Milestones 82
Exhibit 6.61: Divis Laboratories Product Category Portfolio 82
Exhibit 6.62: Divis Laboratories Product List 83
Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012 84
Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio 84
Exhibit 6.65: Dr Reddy’s Therapeutic Areas of Interest 85
Exhibit 6.66: Dr Reddy’s Laboratories - Important Milestones 85
Exhibit 6.67: Dr Reddy’s Labs Top Active Pharmaceutical Ingredients 86
Exhibit 6.68: Dr Reddy’s Labs Top Brands in India 86
Exhibit 6.69: Dr Reddy’s Laboratories Annual Revenue Exhibits 2003-2012 87
Exhibit 6.70: Dr Reddy’s Laboratories Historical Revenue Exhibits 2003-2012 (Global) 87
Exhibit 6.71: Dr Reddy’s Laboratories Geographical Revenue Percentage 2012 88
Exhibit 6.72: Dr Reddy’s Key Brand Revenue in Russia 2011-2012 88
Exhibit 6.73: Dr Reddy’s Key Brand Revenue in India 2011-2012 88
Exhibit 6.74: Dr Reddy’s Therapeutic Agents and Classes undergoing Clinical Trials 89
Exhibit 6.75: Lupin Significant Milestones 89
Exhibit 6.76: Lupin Ltd Formulations Product Portfolio 91
Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio 92
Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution 93
Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012 94
Exhibit 6.80: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012 94
Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012 94
Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012 95
Exhibit 6.83a: Lupin Ltd Profit Before Tax 2008-2012 95
Exhibit 6.83b: Lupin Ltd Formulation Sales 2006-2012 Indian Market 96
Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking 96
Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth 96
Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market 97
Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market 97
Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market 97
Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market 97
Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market 97
Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market 97
Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market 98
Exhibit 6.92: Lupin Ikonic Key Products and Rank in the Indian Market 98
Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012 98
Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market 99
Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market 99
Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012 99
Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area 100
Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio 100
Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise 100
Exhibit 6.100: Mankind Pharma Company Divisions 101
Exhibit 6.101: Mankind Pharma Key Milestones 101
Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest 102
Exhibit 6.103: Mankind Pharma Prescription Product Areas 102
Exhibit 6.104: Mankind Pharma Top Ten Brands 102
Exhibit 6.105: Mankind Pharma Diabetic Product Brands 102
Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands 103
Exhibit 6.107: Mankind Pharma Cough Product Brands 103
Exhibit 6.108: Mankind Pharma Malaria Product Brands 103
Exhibit 6.109: Mankind Pharma Migraine Product Brands 103
Exhibit 6.110: Mankind Pharma Anti-viral Product Brands 103
Exhibit 6.111: Mankind Pharma Steroid Product Brands 103
Exhibit 6.112: Mankind Pharma Dermatology Product Brands 104
Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands 104
Exhibit 6.114: Mankind Pharma Gynaecology Product Brands 104
Exhibit 6.115: Mankind Pharma Antibiotic Product Brands 105
Exhibit 6.116: Mankind Pharma Asthmatic Product Brands 105
Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure 107
Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest 107
Exhibit 6.119: Panacea Biotech Leading Brands in India 107
Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio 108
Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range 108
Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range 108
Exhibit 6.123: Panacea Biotech Vaccine Portfolio 109
Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio 109
Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio 109
Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio 109
Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio 109
Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio 110
Exhibit 6.129: Panacea Biotech Constipation Product Portfolio 110
Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio 110
Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio 110
Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care 110
Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management 110
Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) - Tuberculosis Treatment 110
Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) - Gastrointestinal Treatment 111
Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) - Anti-Haemorrhoidal 111
Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) - Penicillins 111
Exhibit 6.138: Panacea Biotech Current Patents for Licencing 111
Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012 113
Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012 113
Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012 113
Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114
Exhibit 6.143: Key Milestones in Piramal Group History 114
Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012 117
Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales 2012 117
Exhibit 6.146: Piramal Pharma Solutions Salesfrom Domestic and International Assets 2011-2012 118
Exhibit 6.147: Piramal Oncology Therapeutic Pipeline 119
Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline 119
Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline 119
Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline 119
Exhibit 6.151: Ranbaxy Laboratories - Therapeutic Markets of Interest 120
Exhibit 6.152: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System 120
Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics 120
Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006 121
Exhibit 6.155: List of Ranbaxy Subsidiary Companies 121
Exhibit 6.156: Ranbaxy - Future Therapeutic Areas 122
Exhibit 6.157: Ranbaxy Global Sales by Geographical Region 124
Exhibit 6.158: Ranbaxy Global Sale Figures by Geographical Region 124
Exhibit 6.159: Ranbaxy Geographical Market Share Percentage 124
Exhibit 6.160: Ranbaxy Developed and Emerging Market Share 125
Exhibit 6.161: Ranbaxy Sales Figures, USA and Canada 125
Exhibit 6.162: Ranbaxy Sales Figures, Europe 126
Exhibit 6.163: Ranbaxy Top Sellers in India 126
Exhibit 6.164: Ranbaxy Sales Figures, India 127
Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India 127
Exhibit 6.166: Ranbaxy Launches by Geographical Region 127
Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas 128
Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas 128
Exhibit 6.169: Reliance Life Sciences Clinical Research Services 129
Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas 129
Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas 129
Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio 129
Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio 129
Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio 129
Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio 129
Exhibit 6.176: Reliance Life Science RandD Activities 130
Exhibit 6.177: Serum Institute of India Significant Milestones 131
Exhibit 6.178a: Serum Institute of India Manufactured Products 131
Exhibit 6.178b: Serum Institute of India Marketed Products 132
Exhibit 6.179: Serum Institute of India Exported Products 132
Exhibit 6.180: Serum Institute of India Product Pipeline 133
Exhibit 6.181: Sun Pharmaceuticals - Important Milestones 134
Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage) 135
Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions) 136
Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012 136
Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India 136
Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area 137
Exhibit 6.187: Zydus Research Centre Speciality Areas of Research 138
Exhibit 6.188: Zydus Cadila Vaccine RandD Areas of Research 138
Exhibit 6.189: Zydus Cadila Global ‘Beyond the Billion’ Business Development Strategy 139
Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market 139
Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline 140
Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline 140
Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012 141
Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012 142
Exhibit 6.195: Zydus Cadila List of Subsidiary Companies 142
Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012 143
Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest 143
Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market 144
Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020 144
Exhibit 7.3: Strengths of the Indian Pharmaceutical Market 145
Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market 145
Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market 146
Exhibit 7.6: Threats to the Indian Pharmaceutical Market 148
Exhibit 8.1: Aurobindo Pharma Key Contact Details 149
Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel 149
Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details 150
Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors 150
Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details 151
Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors 152
Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team 152
Exhibit 8.8: Cipla Executive Directors 153
Exhibit 8.9: Cipla Non-Executive/Independent Directors 153
Exhibit 8.10: Cipla Corporate Contact Details 153
Exhibit 8.11: Divis Laboratories Key Contact Details 153
Exhibit 8.12: Divis Laboratories Key People 155
Exhibit 8.13: Dr Reddy’s Laboratories Contact Information 155
Exhibit 8.14: Dr Reddy’s Laboratories Key People 156
Exhibit 8.15: Dr Reddy’s Laboratories Board of Directors 156
Exhibit 8.16: Dr Reddy’s Audit Committee Members 157
Exhibit 8.17: Dr Reddy’s Nomination, Governance and Compensation Committee Members 157
Exhibit 8.18: Dr Reddy’s Risk Management Committee Members 157
Exhibit 8.19: Dr Reddy’s Science, Technology and Operations Committee Members 157
Exhibit 8.20: Dr Reddy’s Shareholders’ Grievance Committee Members 157
Exhibit 8.21: Dr Reddy’s Investment Committee Members 157
Exhibit 8.22: Dr Reddy’s Management Committee Members 157
Exhibit 8.23: Lupin Board of Directors 157
Exhibit 8.24: Lupin Key Management Players 158
Exhibit 8.25: Lupin Ltd General Contact Details 158
Exhibit 8.26: Panacea Biotech - Whole Time Directors 158
Exhibit 8.27: Panacea Biotech - Independent Directors 158
Exhibit 8.28: Panacea Biotech - Investor Contact Details 159
Exhibit 8.29: Panacea Biotech - General Contact Details 159
Exhibit 8.30: Reliance Life Sciences - General Contact Details 160

























View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Global Markets for Enzymes in Industrial Applications

Global Markets for Enzymes in Industrial Applications

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Widespread research in the field of industrial enzymes has revealed the influence of enzyme technology in almost every sector of industrial activity, ranging from technical field to food, feed and healthcare ...

Biosimilar Index: Tracking the Global Biosimilar Pipeline

Biosimilar Index: Tracking the Global Biosimilar Pipeline

  • $ 5 369
  • Industry report
  • April 2014
  • by Firstword Pharma

Biosimilar Index answers your questions, such as... - There are 15 biosimilar and non-comparable biologic (NCB) versions of bevacizumab (Avastin; Roche) in clinical development; with the Biosimilar Index ...

Protein Hydrolysis Enzymes Market by Sources (Microorganisms, Animals, Plants), Applications (Detergent Industry, Pharmaceuticals, Food Industry and Others), & Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019

Protein Hydrolysis Enzymes Market by Sources (Microorganisms, Animals, Plants), Applications (Detergent Industry, Pharmaceuticals, Food Industry and Others), & Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019

  • $ 4 650
  • Industry report
  • April 2014
  • by MarketsandMarkets

The enzymes which are very specific to protein hydrolysis are protease enzymes and they are classified under the “hydrolases group”. Protease enzymes refer to a group of enzymes whose catalytic function ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.